Matt Miksic
Stock Analyst at Barclays
(3.92)
# 643
Out of 4,712 analysts
254
Total ratings
61.76%
Success rate
5.46%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZBH Zimmer Biomet Holdings | Maintains: Underweight | $125 → $118 | $106.82 | +10.47% | 6 | Dec 12, 2024 | |
| EW Edwards Lifesciences | Maintains: Overweight | $85 → $88 | $74.81 | +17.63% | 27 | Dec 2, 2024 | |
| MDT Medtronic | Maintains: Overweight | $105 → $109 | $81.40 | +33.91% | 21 | Nov 26, 2024 | |
| ATEC Alphatec Holdings | Maintains: Overweight | $19 → $20 | $9.12 | +119.30% | 1 | Nov 19, 2024 | |
| PODD Insulet | Maintains: Equal-Weight | $220 → $234 | $263.33 | -11.14% | 7 | Nov 11, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Overweight | $58 → $60 | $36.61 | +63.89% | 5 | Nov 8, 2024 | |
| ABT Abbott Laboratories | Maintains: Overweight | $143 → $149 | $114.31 | +30.35% | 27 | Nov 5, 2024 | |
| SYK Stryker | Maintains: Overweight | $402 → $418 | $366.49 | +14.05% | 22 | Oct 31, 2024 | |
| INMD InMode | Maintains: Overweight | $29 → $27 | $16.95 | +59.29% | 10 | Oct 14, 2024 | |
| BSX Boston Scientific | Maintains: Overweight | $78 → $86 | $89.86 | -4.30% | 15 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $85 → $93 | $83.10 | +11.91% | 13 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $138 → $113 | $79.54 | +42.07% | 5 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $490 → $510 | $527.22 | -3.27% | 6 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $16 | $13.76 | +16.28% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $57 → $61 | $46.99 | +29.81% | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $18 | $17.83 | +0.95% | 4 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $52 → $54 | $29.18 | +85.06% | 19 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $158 → $162 | $145.27 | +11.52% | 10 | Oct 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $96 | $85.38 | +12.44% | 9 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $70.06 | +42.73% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $207.57 | +101.38% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $13.33 | +110.05% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $18.95 | +253.56% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $480 | $12.92 | +3,615.17% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $22.01 | +295.27% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $3.18 | +686.16% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $9.27 | -2.91% | 1 | Dec 12, 2016 |
Zimmer Biomet Holdings
Dec 12, 2024
Maintains: Underweight
Price Target: $125 → $118
Current: $106.82
Upside: +10.47%
Edwards Lifesciences
Dec 2, 2024
Maintains: Overweight
Price Target: $85 → $88
Current: $74.81
Upside: +17.63%
Medtronic
Nov 26, 2024
Maintains: Overweight
Price Target: $105 → $109
Current: $81.40
Upside: +33.91%
Alphatec Holdings
Nov 19, 2024
Maintains: Overweight
Price Target: $19 → $20
Current: $9.12
Upside: +119.30%
Insulet
Nov 11, 2024
Maintains: Equal-Weight
Price Target: $220 → $234
Current: $263.33
Upside: -11.14%
Tandem Diabetes Care
Nov 8, 2024
Maintains: Overweight
Price Target: $58 → $60
Current: $36.61
Upside: +63.89%
Abbott Laboratories
Nov 5, 2024
Maintains: Overweight
Price Target: $143 → $149
Current: $114.31
Upside: +30.35%
Stryker
Oct 31, 2024
Maintains: Overweight
Price Target: $402 → $418
Current: $366.49
Upside: +14.05%
InMode
Oct 14, 2024
Maintains: Overweight
Price Target: $29 → $27
Current: $16.95
Upside: +59.29%
Boston Scientific
Aug 22, 2024
Maintains: Overweight
Price Target: $78 → $86
Current: $89.86
Upside: -4.30%
Aug 8, 2024
Maintains: Overweight
Price Target: $85 → $93
Current: $83.10
Upside: +11.91%
Jul 29, 2024
Maintains: Equal-Weight
Price Target: $138 → $113
Current: $79.54
Upside: +42.07%
Jul 23, 2024
Maintains: Overweight
Price Target: $490 → $510
Current: $527.22
Upside: -3.27%
Mar 5, 2024
Maintains: Underweight
Price Target: $13 → $16
Current: $13.76
Upside: +16.28%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $57 → $61
Current: $46.99
Upside: +29.81%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $17 → $18
Current: $17.83
Upside: +0.95%
Feb 12, 2024
Maintains: Overweight
Price Target: $52 → $54
Current: $29.18
Upside: +85.06%
Oct 12, 2023
Maintains: Equal-Weight
Price Target: $158 → $162
Current: $145.27
Upside: +11.52%
May 13, 2022
Assumes: Outperform
Price Target: $96
Current: $85.38
Upside: +12.44%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $70.06
Upside: +42.73%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $207.57
Upside: +101.38%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $13.33
Upside: +110.05%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $18.95
Upside: +253.56%
Jan 7, 2022
Initiates: Outperform
Price Target: $480
Current: $12.92
Upside: +3,615.17%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $22.01
Upside: +295.27%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $3.18
Upside: +686.16%
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $9.27
Upside: -2.91%